New Glucose-Lowering Agents for Diabetic Kidney Disease
In conclusion, currently available trials have demonstrated renoprotective effects for certain glucagon-like peptide-1 receptor agonists, liraglutide and semaglutide, and the sodium-glucose cotransporter 2 inhibitors, empagliflozin and canagliflozin. Dipeptidyl peptidase-4 inhibitors did not show a significant renoprotective effect. Nevertheless, larger studies with respect to renoprotective effects of these 3 drug classes are currently being performed, and thus, no conclusions for all of these agents can yet be made.
Source: Advances in Chronic Kidney Disease - Category: Urology & Nephrology Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Empagliflozin | Endocrinology | Heart | Invokana | Jardiance | Sodium | Study | Urology & Nephrology | Victoza | Weight Loss